查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496701

進行性遺傳性肝內膽汁淤積治療市場：按藥物類型、分銷管道和最終用戶分類 - 全球預測 2024-2030

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

進行性遺傳性肝內膽汁淤積治療市場規模預估至2023年為1.1352億美元，2024年達到1.1862億美元，2030年達到1.5614億美元，複合年成長率預估為4.65%。

進行性遺傳性肝內膽汁淤積（PFIC）是一組罕見的遺傳性肝損傷，由膽道上皮轉運蛋白缺陷引起，導致膽汁形成和流動受損，進行性肝臟疾病。如果不及時治療，該疾病的嚴重程度和進展可能會導致肝功能衰竭。治療策略旨在控制症狀、改善肝功能並防止進一步損害。醫療保健專業人員和公眾對 PFIC 的認知不斷提高，可以實現更快、更準確的診斷。先進的基因檢測和分子診斷在識別受影響個體方面發揮著重要作用，從而可以進行早期干預。 FDA 和 EMA 等監管機構認知到對罕見疾病（包括 PFIC）進行標靶治療的必要性。這導致了加快審查流程、津貼計劃和其他針對罕見疾病特異性治療方法開發的獎勵。 PFIC的治療在技術上是透過新療法或肝臟移植，但價格昂貴。這可能會對患者、家庭和醫療保健系統造成沉重負擔，並限制獲得所需治療的機會。新療法和肝臟移植的高昂費用可能對患者、家庭和醫療保健系統造成沉重負擔，限制了獲得所需治療的機會。該領域的研究和開發帶來了創新的治療方法，包括新藥物和改進的手術技術。這正在擴大治療策略組合併創造市場成長機會。

主要市場統計
基準年[2023] 11352萬美元
預測年份 [2024] 11862萬美元
預測年份 [2030] 1.5614億美元
複合年成長率（%） 4.65%

區域洞察

成熟的醫療基礎設施和不斷上漲的醫療成本正在支持美洲 PFIC 治療市場的成長。此外，由患者支持組織和政府支持的針對罕見疾病的健康措施在該地區非常活躍，提高了意識和診斷率。包括孤兒藥指定在內的監管激勵措施鼓勵製藥公司投資研發，從而形成強大的治療產品線。由於對罕見疾病治療的認知提高和醫療設施的改善，加拿大和南美國家的市場不斷成長。亞太地區的 PFIC 治療市場呈現出多樣化的景象，日本和澳洲等國家在醫療保健創新和治療取得方面處於領先地位。這些國家對 PFIC 及其治療方案的認知相對較高，並得到強大的醫療保健系統和支持罕見疾病管理的政策的支持。在有利的監管政策、發達的醫療保健系統和高認知度的推動下，歐洲已成為 PFIC 研究和治療的主導地區。歐洲藥品管理局 (EMA) 在快速核准治療罕見疾病（包括 PFIC）的藥物方面發揮關鍵作用。該地區針對罕見疾病採取的統一方法（以跨境醫療保健措施為代表）使 PFIC 患者受益匪淺。中東和非洲擁有先進的醫療保健系統，開始認知並解決 PFIC。

FPNV定位矩陣

FPNV 定位矩陣對於評估進行性遺傳性肝內膽汁淤積治療市場中供應商的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對進行性遺傳性肝內膽汁淤積治療市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對進行性遺傳性肝內膽汁淤積治療市場當前地位的全面評估將幫助公司做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 改善的醫療基礎設施增加了對進行性遺傳性肝內膽汁淤積症的檢測
      • 擴大患者權益團體的角色以擴大 PFIC 治療
    • 抑制因素
      • 獲得 PFIC 治療和費用負擔問題
    • 機會
      • PFIC 研究和診斷技術的進展
      • 政府對 PFIC 治療的有利核准
    • 任務
      • PFIC 疾病管理和治療效果的複雜性
  • 市場區隔分析
    • 藥物類型：增加考來烯胺的使用以降低肝臟和血液中膽汁酸的濃度
    • 通路：首選網路藥局，永續且方便地取得處方藥。
    • 最終使用者：PFIC 治療可能在醫院進行，以處理 PFIC 的嚴重併發症
  • 市場趨勢分析
    • 美洲對 PFIC 治療的監管核准增加
    • 政府對罕見疾病治療方法進展的積極支持，並加強推動亞太地區的醫療保健服務和解決方案。
    • 增加研究活動，探索有效的治療方法和標準，並在歐洲、中東和非洲地區建立製藥業
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章進行性遺傳性肝內膽汁淤積治療市場：依藥物類型

  • 消膽胺
  • 利福平
  • 熊去氧膽酸

第7章進行性遺傳性肝內膽汁淤積治療市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章進行性遺傳性肝內膽汁淤積治療市場：依最終用戶

  • 門診手術中心
  • 醫院
  • 專科診所

第9章北美與南美遺傳性肝內膽汁淤積症治療市場的進行性

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區遺傳性肝內膽汁淤積症治療市場的進行性

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲進行性遺傳性肝內膽汁淤積治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • FDA核准Livmarli 用於治療進行性遺傳性肝內膽汁淤積症患者的搔癢症
    • 加拿大政府將撥款 2,000 萬加元，用於改善患有罕見疾病（包括進行性遺傳性肝內膽汁淤積症）的兒童的健康狀況。
    • 法國政府向 Vivet Therapeutics 授予 490 萬歐元津貼，用於創新基因療法的開發
    • 加拿大衛生署核准Bylvay (odevixibat) 治療 PFIC 相關搔癢
    • 北康成藥 CAN108 NDA 獲 NMPA核准
    • UKRI 投入 1400 萬英鎊進一步研究進行進行性遺傳性肝內膽汁淤積症和其他罕見疾病
    • Jadeite Medicines 在日本透過 3 期試驗和孤兒藥資格認定推進 PFIC 的治療
    • 印度已撥款40億盧比加強罕見疾病治療，並專注於加強PFIC和患者照護。
    • Ipsen 透過策略收購 Albireo Pharma 加強罕見疾病藥物供應

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-AD517FAAA5F2

[187 Pages Report] The Progressive Familial Intrahepatic Cholestasis Treatment Market size was estimated at USD 113.52 million in 2023 and expected to reach USD 118.62 million in 2024, at a CAGR 4.65% to reach USD 156.14 million by 2030.

Progressive familial intrahepatic cholestasis (PFIC) is a group of rare genetic liver disorders that occur due to defects in the biliary epithelial transporters, leading to impaired bile formation and flow and resulting in progressive liver disease. The severity and progression of the disease lead to liver failure if left untreated. Treatment strategies aim to manage symptoms, improve liver function, and prevent further damage. A growing awareness of PFIC among healthcare professionals and the public leads to earlier and more accurate diagnoses. Advanced genetic testing and molecular diagnostics have played a crucial role in identifying affected individuals, allowing for earlier intervention. Regulatory bodies such as the FDA and EMA have recognized the need for treatments targeting rare diseases, including PFIC. This has led to expedited review processes, grant programs, and other incentives for the development of therapies specifically aimed at rare conditions. The treatment of PFIC, precisely with novel therapies and liver transplantation, can be costly. This significantly burdens patients, families, and healthcare systems, potentially limiting access to necessary treatments. The high cost of treatment with novel therapies and liver transplantation poses a significant burden on patients, families, and healthcare systems, potentially limiting access to necessary treatments. Research and development in the field have led to innovative treatment options, including new pharmaceutical drugs and improved surgical techniques. This has expanded the treatment strategy portfolio, creating market growth opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 113.52 million
Estimated Year [2024] USD 118.62 million
Forecast Year [2030] USD 156.14 million
CAGR (%) 4.65%

Regional Insights

The well-established healthcare infrastructure and increased healthcare expenditure support the growth of the PFIC treatment market in the Americas. Furthermore, the region benefits from active patient advocacy groups and government-supported health initiatives aimed at rare diseases, enhancing awareness and diagnosis rates. Regulatory incentives, including orphan drug designation, encourage pharmaceutical companies to invest in research and development, leading to a robust pipeline of therapeutic drugs. Canada and South American countries represent a growing market with increasing awareness and improving healthcare facilities for the treatment of rare diseases. The APAC region presents a diverse landscape for the PFIC treatment market, with countries including Japan and Australia leading in healthcare innovation and access to treatments. These countries have relatively high awareness of PFIC and its treatment options, supported by strong healthcare systems and policies favoring rare disease management. Europe is a leading region in terms of PFIC research and treatment, driven by favorable regulatory policies, extensive healthcare systems, and high levels of awareness. The European Medicines Agency (EMA) plays a crucial role in the fast-tracking approval of drugs for rare diseases, including PFIC. The region's unified approach to tackling rare diseases, exemplified by cross-border healthcare initiatives, significantly benefits PFIC patients. The Middle East and Africa, with advanced healthcare systems, have begun to recognize and address PFIC.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Progressive Familial Intrahepatic Cholestasis Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
      • Expanding role of patient advocacy groups to expand PFIC treatments
    • Market Restraints
      • Access and affordability issues of PFIC treatments
    • Market Opportunities
      • Advancements in PFIC research and diagnostic technologies
      • Favorable government approvals for PFIC treatments
    • Market Challenges
      • Complexity in PFIC disease management and treatment efficacy
  • Market Segmentation Analysis
    • Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
    • Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
    • End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients

The U.S. Food and Drug Administration (FDA) has officially approved Mirum Pharmaceuticals' Livmarli oral solution in a significant advancement for patients with Progressive Familial Intrahepatic Cholestasis (PFIC), aimed at treating cholestatic pruritus in individuals aged five years and above. This decision is supported by extensive research efforts and a compelling accumulation of clinical data, demonstrating notable progress in several key health indicators, particularly in alleviating pruritus among affected children. [Published On: 2024-03-14]

Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis

The Canadian government allocates an investment of CAD 20 million aimed at improving health outcomes. This funding initiative is part of a comprehensive strategy to address the challenges faced by children living with rare conditions, such as progressive familial intrahepatic cholestasis (PFIC), by enhancing access to specialized care, supporting innovative research, and fostering the development of new treatments. This investment highlights the government's commitment to elevating the standard of care for vulnerable populations, ensuring that children with rare diseases can look forward to a brighter, healthier future. [Published On: 2024-02-28]

French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"

The French Government, through its France Health Innovation Plan 2023, allocated a Euro 4.9 million (USD 5.3 million) grant to Vivet Therapeutics. This Paris-based biotech firm spearheads the development of VTX-806, a gene therapy aimed at combating cerebrotendinous xanthomatosis (CTX), the buildup of cholesterol in nerve cells. This initiative falls within the broader strategic framework of accelerating Biotherapies and Bioproduction in innovative therapies. [Published On: 2024-02-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Progressive Familial Intrahepatic Cholestasis Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Calliditas Therapeutics AB, CANbridge Pharmaceuticals Inc., Centurion Laboratories Private Limited, CymaBay Therapeutics, Inc., Enomark, Glenmark Pharmaceuticals Limited, Healthy Life Pharma Pvt. Ltd., Hebei Xingang Pharmaceutical Co., Ltd., Intercept Pharmaceuticals, Inc., Ipsen Pharma, Jackson Laboratories Pvt Ltd., Macleods Pharmaceuticals Ltd., Mirum Pharmaceuticals, Inc., Novartis AG, Par Pharmaceuticals, Inc. by Endo International PLC, Pfizer Inc., Sanofi S.A., SiNi Pharma Pvt. Ltd., Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivet Therapeutics, Wellona Pharma, and Zoic Biotech Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Cholestyramine
    • Rifampicin
    • Ursodeoxycholic Acid
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-Users
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
      • 5.1.1.2. Expanding role of patient advocacy groups to expand PFIC treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Access and affordability issues of PFIC treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in PFIC research and diagnostic technologies
      • 5.1.3.2. Favorable government approvals for PFIC treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in PFIC disease management and treatment efficacy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
    • 5.2.2. Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
    • 5.2.3. End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
  • 5.3. Market Trend Analysis
    • 5.3.1. Rising approvals for PFIC treatment from regulatory bodies in the Americas
    • 5.3.2. Favorable government support for advancing therapeutics for rare diseases and growing efforts to advance medical and healthcare services and solutions in the APAC region.
    • 5.3.3. Increasing research activities to explore effective treatments and standards and the well-established pharmaceutical industry of the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Cholestyramine
  • 6.3. Rifampicin
  • 6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients
    • 12.3.2. Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis
    • 12.3.3. French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"
    • 12.3.4. Approval of Bylvay (odevixibat) by Health Canada for PFIC-Related Pruritus
    • 12.3.5. CANbridge Pharmaceuticals Gains NMPA Approval for CAN108 NDA
    • 12.3.6. UKRI Allocates GBP 14 Million to Advance Research on Progressive Familial Intrahepatic Cholestasis and Other Rare Diseases
    • 12.3.7. Jadeite Medicines Advances Treatment for PFIC with Phase 3 Trial and Orphan Drug Designation in Japan
    • 12.3.8. India Boosts Rare Diseases Treatment, Allocates INR 40 Crore with a Focus on PFIC and Enhanced Patient Care
    • 12.3.9. Ipsen Enhances Rare Disease Offerings with Strategic Acquisition of Albireo Pharma

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2023 (USD THOUSAND)
  • TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2024-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 31. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 32. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 33. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 34. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 35. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 36. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 37. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 38. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 39. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 40. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 41. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 42. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 43. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 44. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 45. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 46. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 47. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 48. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 49. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 50. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 51. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 52. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 53. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 54. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 55. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 56. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 57. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 58. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 59. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 60. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 61. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 62. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 63. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 64. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 65. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 66. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 67. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 68. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 69. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD THOUSAND)
  • TABLE 70. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD THOUSAND)
  • TABLE 71. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 72. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 73. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 74. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 75. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 76. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 77. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 78. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 79. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 80. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 81. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 82. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 83. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 84. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 85. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 86. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 87. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 88. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 89. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 90. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 91. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 92. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 93. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 94. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 95. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 96. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 97. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 98. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 99. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 100. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 101. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 102. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 103. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 104. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 105. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 106. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 107. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 108. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 109. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 110. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 111. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 112. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 113. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 114. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 115. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 116. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 117. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 118. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 119. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 120. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 121. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 122. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 123. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 124. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 125. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 126. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 127. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 128. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 129. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 130. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 131. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 132. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 133. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 134. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 135. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 136. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 137. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 138. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 139. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 140. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 141. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 142. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 143. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 144. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 145. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 146. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 147. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 148. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 149. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 150. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 159. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 160. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 161. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 162. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 163. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 164. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 165. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 166. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 167. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 168. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 169. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 170. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 171. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 172. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 173. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 174. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 175. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 176. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 177. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 178. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 179. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 180. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 181. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 182. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 183. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 184. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 185. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 186. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 187. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 188. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 189. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 190. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 191. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 192. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 193. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 194. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 195. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 196. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 197. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 198. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 199. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 200. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 201. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 202. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 203. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 204. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 205. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 206. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 207. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 208. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 209. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 210. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 211. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 212. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 213. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 214. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 215. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 216. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 217. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 218. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 219. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 220. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 221. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 222. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 223. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 224. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 225. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 226. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 227. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 228. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 229. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 230. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 231. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 232. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 233. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 234. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 235. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 236. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 237. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 238. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 239. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 240. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 241. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 242. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 243. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 244. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 245. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 246. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 247. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 248. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 249. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE,